Here’s Our Rant About 10x Genomics Inc. (TXG) – News Heater
Home  »  Trending   »  Here’s Our Rant About 10x Genomics Inc. (TXG...

Here’s Our Rant About 10x Genomics Inc. (TXG)

10x Genomics Inc. (NASDAQ:TXG) went up by 11.39% from its latest closing price compared to the recent 1-year high of $208.99. The company’s stock price has collected 17.29% of gains in the last five trading sessions. The Wall Street Journal reported on 02/17/22 that Palantir, DoorDash, Nvidia, Hasbro: What to Watch in the Stock Market Today

Is It Worth Investing in 10x Genomics Inc. (NASDAQ :TXG) Right Now?

Opinions of the stock are interesting as 6 analysts out of 9 who provided ratings for 10x Genomics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

The average price from analysts is $95.00, which is $41.53 above the current price. TXG currently public float of 89.28M and currently shorts hold a 7.57% ratio of that float. Today, the average trading volume of TXG was 1.51M shares.

TXG’s Market Performance

TXG stocks went up by 17.29% for the week, with a monthly drop of -6.61% and a quarterly performance of -31.99%, while its annual performance rate touched -76.93%. The volatility ratio for the week stands at 8.10% while the volatility levels for the past 30 days are set at 8.27% for 10x Genomics Inc. The simple moving average for the period of the last 20 days is 6.20% for TXG stocks with a simple moving average of -55.94% for the last 200 days.

Analysts’ Opinion of TXG

Many brokerage firms have already submitted their reports for TXG stocks, with Cowen repeating the rating for TXG by listing it as a “Outperform.” The predicted price for TXG in the upcoming period, according to Cowen is $205 based on the research report published on October 15th of the previous year 2021.

BofA Securities, on the other hand, stated in their research note that they expect to see TXG reach a price target of $180. The rating they have provided for TXG stocks is “Neutral” according to the report published on September 14th, 2021.

TXG Trading at -6.12% from the 50-Day Moving Average

After a stumble in the market that brought TXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.76% of loss for the given period.

Volatility was left at 8.27%, however, over the last 30 days, the volatility rate increased by 8.10%, as shares surge +1.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.95% lower at present.

During the last 5 trading sessions, TXG rose by +17.29%, which changed the moving average for the period of 200-days by -75.66% in comparison to the 20-day moving average, which settled at $43.80. In addition, 10x Genomics Inc. saw -68.80% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TXG starting from Saxonov Serge, who sale 2,656 shares at the price of $48.76 back on May 23. After this action, Saxonov Serge now owns 968,817 shares of 10x Genomics Inc., valued at $129,516 using the latest closing price.

McAnear Justin J., the Chief Financial Officer of 10x Genomics Inc., sale 967 shares at $48.76 during a trade that took place back on May 23, which means that McAnear Justin J. is holding 59,079 shares at $47,155 based on the most recent closing price.

Stock Fundamentals for TXG

Current profitability levels for the company are sitting at:

  • -10.79 for the present operating margin
  • +84.89 for the gross margin

The net margin for 10x Genomics Inc. stands at -11.87. Equity return is now at value -11.10, with -8.90 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 6.77.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]